XL E2A

Break Apart Probe

Order Number
D-5019-100-OG
Package Size
100 µl
Labels
  
Chromosome
19

Description

XL E2A

The production of XL E2A has been discontinued.

Clinical Details

Acute Lymphoblastic Leukemia (ALL) is the most common type of leukemia in children, representing almost 25 % of pediatric cancer. The majority of patients with ALL demonstrate an abnormal karyotype, either in chromosome number or as structural changes such as translocations, inversions, or deletions.

E2A (also termed TCF3) is the target of three known recurrent genomic rearrangements in ALL. The t(1;19)(q23;p13.3) occurs in approximately 5 % of cases and is the second most common translocation in ALL. The t(17;19)(q22;p13) occurs in about 1 % of ALLs and fuses E2A to the chromosome 17 gene HLF. A recently described cryptic inversion of chromosome 19 fuses E2A to the 19q13.4 gene FB1.

Clinical Applications

  • Acute Lymphoblastic Leukemia (ALL)

Images

XL E2A

XL E2A hybridized to lymphocytes. One normal interphase is shown.

Expected Patterns

Expected Pattern 1

Normal Cell:
Two green-orange fusion signals (2GO).

Expected Pattern 2

Aberrant Cell (typical results):
One green-orange fusion signal (1GO), one separate green (1G) and one orange (1O) signal each resulting from a chromosome break in the relevant locus.

Literature

  • Boomer et al (2001) Leukemia 15:95-102
  • Van der Burg et al (2004) Leukemia 18:895-908
  • Kager et al (2007) Haematologica 92:1561-1564

Downloads

Order Now or Request Assistance

Contact Us »

Contact MetaSystems directly or find your local MetaSystems partner.